Pharmacy

 Bausch + Lomb, the global eye health company, recently announced its entry into the growing Indian pharmaceutical market by signing a Memorandum of Understanding (MoU) with Micro Labs India, a leading provider of quality healthcare products. With this collaboration Bausch + Lomb will be finally entering the Indian pharma market after having a presence in the pharmaceutical vertical worldwide for over two decades. "Our company entered the pharma vertical in the year 1986 but at that time there was less confidence in the Indian pharma market from the company s side, and also we did not get any good collaborative opportunity like this. So we were just waiting for the right moment and the right opportunity," said Harish Natarajan, Managing Director, Bausch + Lomb India.

Through the agreement with Micro Labs, Bausch + Lomb aims to capture part of the rapidly expanding ophthalmic pharmaceuticals market in India, which is expected to reach $300 million by 2015. In addition to gaining access to world-class manufacturing capabilities, Bausch + Lomb will establish dedicated sales and marketing teams. With the help of this collaboration Bausch + Lomb will be launching six pre- and post-operative eye drops in India namely, Moxisurge™, Aquasurge™,   Aquasurge   Max™, Bromvue™, Ketovue™ and a Moxisurge- KT™. While the manufacturing of these products will be taken care of by Micro Labs, Bausch + Lomb will look into setting up of quality processes, co-vigilance system and other such processes. "It gives us immense pleasure to partner with Bausch + Lomb, the most powerful brand in eye health as they enter into the pharmaceutical segment in India," said Anand Surana, Director, Micro Labs, India.